In one paragraphArticle in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
11 authors.
Rouxjeane VenterDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-8710-8166 Jamie van SchalkwykDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Zandile BooiDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Zama MahloboDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-6574-4508 Zaida PalmerDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Grant TheronDSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-9216-2415 Funding
The Center for Innovation in Point-of-Care Technologies for HIV/AIDS atNorthwestern University (C-THAN) Supplemental RequestU54EB027049 · NIBIB · NORTHWESTERN UNIVERSITY · PI Kara M Palamountain · 2018 to 2026
$24.0MRapid Research for Diagnostics Development in TB Network (R2D2 TB Network)U01AI152087 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CATTAMANCHI, ADITHYA, DENKINGER, CLAUDIA MARIA · 2020 to 2024
$19.3MHIV and Mycobacterial Disease in MaliD43TW010350 · FIC · UNIV OF SCIENCES, TECH & TECH OF BAMAKO · PI MAIGA, ALMOUSTAPHA ISSIAKA, MURPHY, ROBERT LEO · 2016 to 2025
$3.0MPre- and post-treatment lung microbiota, metabolome and immune signatures at the site of disease in patients with active pulmonary tuberculosisR01AI136894 · NIAID · STELLENBOSCH UNIVERSITY · PI THERON, GRANT DE VOS · 2019 to 2023
$678kFIC NIH HHS D43 TW010350NIAID NIH HHS R01 AI136894NIAID NIH HHS U01 AI152087NIBIB NIH HHS U54 EB027049
6 · The paper itselfAbstract
Background: Non-sputum-based diagnosis of tuberculosis is a public health priority. Little is known about the feasibility of detecting Methods: We recruited symptomatic adults self-presenting to South African primary care clinics with a sputum Xpert MTB/RIF Ultra (Ultra) result. Cough aerosols were collected on-site by the TB Hotspot Detector, a novel electrostatic aerosol sampler, and tested by Ultra. Environmental and laboratory controls were collected. Predictors of aerosol Results: Among 137 participants, 71 (52%) had medium or high sputum Ultra semiquantitative results and 34 (25%) had negative results. When compared with sputum Ultra detection, AMD detection sensitivity and specificity were 46.6% (95% CI, 42.5%-50.7%) and 76.5% (95% CI, 70.4%-82.5%), respectively. Sensitivity was higher in people with a sputum Ultra semiquantitation category of high (56.9%; 95% CI, 51.1%-62.7%). Factors associated with AMD detection were male sex with a sputum Ultra semiquantitative result of medium or greater (adjusted risk ratio, 3.26; 95% CI, 1.11-9.55; Conclusions: Electrostatic aerosol sampling is feasible in primary care to detect people with infectious tuberculosis. Deployment of this and other practical aerosol-sampling tools might help to characterize predictors of tuberculosis transmission.
Indexed as
cough-generated aerosoldiagnosiselectrostatic samplerMtb aerosolizationMycobacterium tuberculosis
Identifiers
PMID41113324
PMCPMC12534728
What Socratic holds
Textmetadata
Read underepoch 390